---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000537"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:15:47.135019+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors

## Summary
- Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.
- Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.
- OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.
- CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference.

## SEC filing metadata
- accession: 0001641172-25-000537
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/0001641172-25-000537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000537
- JSON: https://secwatch.observer/filing/0001641172-25-000537.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.